Maturation of dendritic cells (DCs) from healthy donors or from breast cancer patients
Taken from "Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency"
Breast Cancer Research 2005;7(3):R326-R335.
Published online 25 Feb 2005
Copyright © 2005 Gervais et al.; licensee BioMed Central LtdData are expressed as the percentage of the cells (with standard error) expressing the CD80, CD83 and CD86 surface markers after treatment of immature DCs with a combination of maturating agents: tumour necrosis factor (TNF)-α/lipopolysaccharide (LPS)/CD40L (= 3); IL-1β/IL-6/TNF-α/prostaglandin (PG)E(= 4–5); and Ribomunyl/Imukin(= 3). Different from corresponding donors in each individual assay.